Cargando…

Effectiveness of two different doses of rituximab for the treatment of rheumatoid arthritis in an international cohort: data from the CERERRA collaboration

BACKGROUND: The approved dose of rituximab (RTX) in rheumatoid arthritis is 1000 mg × 2, but some data have suggested similar clinical efficacy with 500 mg × 2. The purpose of this study was to compare the effectiveness of the regular and low doses given as first treatment course. METHODS: Twelve Eu...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chatzidionysiou, Katerina, Lie, Elisabeth, Nasonov, Evgeny, Lukina, Galina, Hetland, Merete Lund, Tarp, Ulrik, Ancuta, Ioan, Pavelka, Karel, Nordström, Dan C., Gabay, Cem, Canhão, Helene, Tomsic, Matija, van Riel, Piet L. C. M., Gomez-Reino, Juan, Kvien, Tore K., van Vollenhoven, Ronald F.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2016
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4756505/ https://www.ncbi.nlm.nih.gov/pubmed/26883119 http://dx.doi.org/10.1186/s13075-016-0951-z

Ejemplares similares

Erratum to: Effectiveness of two different doses of rituximab for the treatment of rheumatoid arthritis in an international cohort: data from the CERERRA collaboration
por: Chatzidionysiou, Katerina, et al.
Publicado: (2016)

Effectiveness of tocilizumab with and without synthetic disease-modifying antirheumatic drugs in rheumatoid arthritis: results from a European collaborative study
por: Gabay, Cem, et al.
Publicado: (2016)

Comparative effectiveness of subcutaneous tocilizumab versus intravenous tocilizumab in a pan-European collaboration of registries
por: Lauper, Kim, et al.
Publicado: (2018)

Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis
por: Buch, Maya H, et al.
Publicado: (2011)

Influence of FCGR3A genotype on the therapeutic response to rituximab in rheumatoid arthritis: an observational cohort study
por: Kastbom, Alf, et al.
Publicado: (2012)

Imputing missing data of function and disease activity in rheumatoid arthritis registers: what is the best technique?
por: Mongin, Denis, et al.
Publicado: (2019)

The Effects of Rituximab on Lipids, Arterial Stiffness and Carotid Intima-Media Thickness in Rheumatoid Arthritis
por: Novikova, Diana S., et al.
Publicado: (2016)

Opportunities and challenges for real-world studies on chronic inflammatory joint diseases through data enrichment and collaboration between national registers: the Nordic example
por: Chatzidionysiou, Katerina, et al.
Publicado: (2018)

The impact of patient heterogeneity and socioeconomic factors on abatacept retention in rheumatoid arthritis across nine European countries
por: Finckh, A, et al.
Publicado: (2015)

Evolution of radiographic joint damage in rituximab-treated versus TNF-treated rheumatoid arthritis cases with inadequate response to TNF antagonists
por: Finckh, Axel, et al.
Publicado: (2012)

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs
por: Smolen, Josef S, et al.
Publicado: (2010)

Blocking the effects of interleukin-6 in rheumatoid arthritis and other inflammatory rheumatic diseases: systematic literature review and meta-analysis informing a consensus statement
por: Schoels, Monika M, et al.
Publicado: (2013)

Head-to-head comparison of aggressive conventional therapy and three biological treatments and comparison of two de-escalation strategies in patients who respond to treatment: study protocol for a multicenter, randomized, open-label, blinded-assessor, phase 4 study
por: Glinatsi, Daniel, et al.
Publicado: (2017)

Predictors of persistent disease activity and long quiescence in systemic lupus erythematosus: results from the Hopkins Lupus Cohort
por: Giannakou, Ioanna, et al.
Publicado: (2018)

Disease activity patterns over time in patients with SLE: analysis of the Hopkins Lupus Cohort
por: Györi, Noémi, et al.
Publicado: (2017)

Immune mediated events timely associated with COVID-19 vaccine. A comment on article by Badier, et al.: “IgA vasculitis in adult patients following vaccination by ChadOx1 nCoV-19”
por: Hočevar, Alojzija, et al.
Publicado: (2022)

Is the risk of infection higher during treatment with secukinumab than with TNF inhibitors? An observational study from the Nordic countries
por: Glintborg, Bente, et al.
Publicado: (2022)

Considerations for improving quality of care of patients with rheumatoid arthritis and associated comorbidities
por: Kvien, Tore K, et al.
Publicado: (2020)

Access to biologic treatment for rheumatoid arthritis in Central and Eastern European (CEE) countries
por: Orlewska, Ewa, et al.
Publicado: (2011)

The Impact of Newer Biological Disease Modifying Anti-Rheumatic Drugs on Cardiovascular Risk Factors: A 12-Month Longitudinal Study in Rheumatoid Arthritis Patients Treated with Rituximab, Abatacept and Tociliziumab
por: Provan, Sella Aarrestad, et al.
Publicado: (2015)

How do we use biologics in rheumatoid arthritis patients with a history of malignancy? An assessment of treatment patterns using Scandinavian registers
por: Chatzidionysiou, Katerina, et al.
Publicado: (2020)

Safety and Efficacy of Atacicept in Combination With Rituximab for Reducing the Signs and Symptoms of Rheumatoid Arthritis: A Phase II, Randomized, Double‐Blind, Placebo‐Controlled Pilot Trial
por: van Vollenhoven, R. F., et al.
Publicado: (2015)

Non-pharmacological Effects in Switching Medication: The Nocebo Effect in Switching from Originator to Biosimilar Agent
por: Kristensen, Lars Erik, et al.
Publicado: (2018)

Drug retention, inactive disease and response rates in 1860 patients with axial spondyloarthritis initiating secukinumab treatment: routine care data from 13 registries in the EuroSpA collaboration
por: Michelsen, Brigitte, et al.
Publicado: (2020)

Interleukin-6 and chronic inflammation
por: Gabay, Cem
Publicado: (2006)

The impact of the COVID-19 pandemic on the global assessments of rheumatology clinimetrics: Data from a mobile application. A comment on article by Nagy E, et al.: “The impact of the COVID-19 pandemic on autoimmune diagnostics in Europe: A lesson to be learned”
por: Tomšič, Nejc, et al.
Publicado: (2022)

Induction maintenance with tumour necrosis factor-inhibitor combination therapy with discontinuation versus methotrexate monotherapy in early rheumatoid arthritis: a systematic review and meta-analysis of efficacy in randomised controlled trials
por: Emamikia, Sharzad, et al.
Publicado: (2016)

Biopsy-verified response of severe lupus nephritis to rituximab (anti-CD20 monoclonal antibody) plus cyclophosphamide after biopsy-documented failure to respond to NIH-protocol cyclophosphamide
por: van Vollenhoven, RF, et al.
Publicado: (2002)

Physicochemical data on aqueous polymeric systems of methyl cellulose and lambda- and kappa-carrageenan: SAXS, rheological, densitometry, and sound velocity measurements
por: Cerar, Jure, et al.
Publicado: (2017)

NLRP3 and CARD8 Polymorphisms Influence Higher Disease Activity in Rheumatoid Arthritis
por: Jenko, Barbara, et al.
Publicado: (2016)

Performance of leflunomide as a steroid-sparing agent in giant cell arteritis: A single-center, open-label study
por: Kramarič, Jelka, et al.
Publicado: (2022)

Differences and similarities between the EULAR/ASAS-EULAR and national recommendations for treatment of patients with psoriatic arthritis and axial spondyloarthritis across Europe
por: Michelsen, Brigitte, et al.
Publicado: (2023)

A multicentre, randomised, controlled, open-label pilot study on the feasibility of discontinuation of adalimumab in established patients with rheumatoid arthritis in stable clinical remission
por: Chatzidionysiou, Katerina, et al.
Publicado: (2016)

Rituximab in Membranous Nephropathy
por: Gauckler, Philipp, et al.
Publicado: (2021)

Commonalities and differences in set-up and data collection across European spondyloarthritis registries — results from the EuroSpA collaboration
por: Linde, Louise, et al.
Publicado: (2023)

Evidence for treating rheumatoid arthritis to target: results of a systematic literature search update
por: Stoffer, Michaela A, et al.
Publicado: (2016)

Comparisons of 7- to 78-joint ultrasonography scores: all different joint combinations show equal response to adalimumab treatment in patients with rheumatoid arthritis
por: Hammer, Hilde Berner, et al.
Publicado: (2011)

Multifocal Thrombophlebitis and Orbital Cellulitis
por: Hočevar, Alojzija, et al.
Publicado: (2020)

Tuberculosis among patients treated with TNF inhibitors for rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis in Slovenia: a cohort study
por: Rotar, Ziga, et al.
Publicado: (2020)

COVID-19 among patients with giant cell arteritis: a single-centre observational study from Slovenia
por: Kramarič, Jelka, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_kfu1ln2h2d5gv33ctoik3qqh2q